Communiqués Regen BioPharma, Inc. OTC Markets

Actions

RGBPP

US75886M4096

Marché Fermé - OTC Markets Autres places de cotation 19:28:14 17/06/2024			Varia. 5j.	Varia. 1 janv.
1,5 ^USD	+48,51 %		0,00 %	-36,40 %

24/04	Regen BioPharma, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI
09/02	Regen Biopharma, Inc. dépose une demande de brevet provisoire pour l'accélération de la reconstitution hématopoïétique après un traumatisme ou une pathologie chronique par l'administration de cellules progénitrices endothéliales dérivées de cellules souches ou de cellules endothéliales.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Regen BioPharma : Material Event - Form 8-K	29/04	PU
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05/02	PR
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20/09/23	AQ
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08/08/23	PR
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07/02/23	AQ
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23/01/23	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19/01/23	AQ
Regen BioPharma : Private Placement - Form 8-K	21/11/22	PU
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	21/11/22	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	18/11/22	AQ
REGEN BIOPHARMA INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	15/11/22	AQ
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events (form 8-K)	14/11/22	AQ
REGEN BIOPHARMA INC : Other Events (form 8-K)	20/09/22	AQ
REGEN BIOPHARMA INC : Other Events (form 8-K)	10/08/22	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	22/07/22	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	20/07/22	AQ
Aplastic Anemia Pipeline, Therapies, Drugs and Key pharma players involved by DelveInsight \| Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others	14/07/22	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities, Other Events (form 8-K)	17/05/22	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	21/04/22	AQ
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	18/03/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Regen BioPharma, Inc. OTC Markets

Actions

RGBPP

US75886M4096

Communiqués

Filtres